The indicators of general clinical methods as prognostic markers of the severity of systemic scleroderma complicated by the development of pneumosclerosis.

O. V. Karaseva, V. V. Rodionova


Purpose: to define clinical prognostic markers for evaluation of inflammation activity and prognosis of complications development in patients with systemic scleroderma. Materials and methods: The study included 32 people, all women, the average age – 43.2±2.23 years. All the examined patients (n=32) were divided into two groups: the main group (n=21) – patients with systemic scleroderma and concomitant pulmonary tissue involvement – pneumosclerosis. Group II (n=11) included patients with systemic scleroderma without signs of pneumosclerosis. The duration of the disease was 8.1±0.03 years. Patients underwent clinico-laboratory and anthropometric studies, chest radiography in two projections, questionnaire of mMRС for assessing the symptoms of dyspnea, blood saturation was measured with a pulse oximeter EchoCG, if necessary – computed tomography of light high resolution was performed and other general clinical studies in accordance with diagnosis, if necessary. Results and discussion: Patients of groups I and II had bilateral reinforcement of the pulmonary pattern mainly in the lower and middle sections. In Group I patients in the basal regions there were also single cyst-like changes, sometimes sections of the honeycomb lung, bronchiectasis, pleural adhesions. Patients of group II showed signs of focal pneumofibrosis (3 patients), who had pneumonia in anamnesis. There was a tendency of increased pressure in the pulmonary artery in patients with the presence of pulmonary tissue lesions, a decrease in the CSR of the left ventricle. When analyzing the data of the rheumatic complex and individual immunogram indices, the level of CIC and rheumatoid factor was higher in patients of group II, and the level of cryoglobulins was significantly increased in group I patients. In patients of group I, in addition to the increase in cryoglobulins, index of С-reactive protein (CRP) and ESR was increased. Conclusion: The affection of the lungs with the development of pneumosclerosis in patients with systemic scleroderma complicates the course of the disease, contributes to worsening of patients’ condition and formation of unfavorable prognosis. The increase in the level of cryoglobulins and CRP can be used not only to assess inflammation activity but also to predict the development of complications, it requires revision of the treatment of the main disease.


scleroderma; pulmonary pneumosclerosis; general clinical methods


Dzyak GV. [Affection of respiratory organs in rheumatological practice]. Ukrainian pulmonary journl. 2000;1:5-11. Russian.

Karaseva OV, Rodionova VV, Shevtsova AI. [Dynamics of acute-phase indices in patients with idio­pathic pulmonary fibrosis during treatment]. Abstracts of scientific reports of the scientific-practical conference "Actual questions of internal medicine". Dnipropetrovsk. 2016;84-85. Ukrainian.

Fischer A, Kong AM, Swigris JJ, Cole AL, Rai­mundo K. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. J Rheumatol. 2018 Feb;45(2):235-41. doi: 10.3899/jrheum.170307. Epub 2017 Nov 15.

Antoniou KM,MargaritopolousGA,GohNS, et al. Combined pulmonary fibrosis and emphysema in scle­roderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheum. 2016 Apr;68(4):1004-12. [PubMed].

Purokivi M, Hodgson U, Myllärniemi M, Salo­maa ER, Kaarteenaho R. Are physicians in primary health care able to recognize pulmonary fibrosis? Eur Clin Res­pir J. 2017 Feb 20;4(1):1290339. doi: 10.1080/20018525.2017.1290339. eCollection 2017.

Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis – a lethal component of systemic sclerosis. Nat Rev Rheumatol. 2014;10:390-402.

Karas’ova OV, Khmel ES, Kovalenko EN, Ro­dio­nova VV. The markers of inflammatory process ac­tivity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis. European respiratory journal Volume 40, supplement 56, september 2012 Abstracts. 22nd An­nual CongressVienna,Austria1-5 September 2012;660. (P3629).

King TE Jr, Pardo A, Selman M. Idiopathic pul­monary fibrosis. Lancet. 2011 Dec 3;378(9807):1949-61. doi: 10.1016/S0140-6736(11)60052-4. Epub 2011 Jun 28.

Keith C Meyer. Pulmonary fibrosis, part I: epi­demiology, pathogenesis, and diagnosis. Expert Review of Respiratory Medicine. 2017;11(5).

MoraAL, Bueno M, Rojas M. Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis. J Clin Invest. 2017 Feb 1;127(2):405-14. doi: 10.1172/JCI87440. Epub 2017 Feb 1.

Richeldi L, Collard HR, Jones MG. Idiopathic pul­monary fibrosis. Lancet. 2017 May 13;389(10082):1941-52. doi: 10.1016/S0140-6736(17)30866-8. Epub 2017 Mar 30.

Suzuki A, Kondoh Y. The clinical impact of major comorbidities on idiopathic pulmonary fibrosis. Respir Investig. 2017 Mar;55(2):94-103. doi: 10.1016/j.resinv.2016.11.004. Epub 2017 Jan 14.

Walkoff L1, White DB1, Chung JH2, Asante D3, Cox CW1. The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis.J Thorac Imaging. 2018 Jan 16. doi: 10.1097/RTI.0000000000000319. [Epub ahead of print]

GOST Style Citations

  1. Дзяк Г.В. Поражение органов дыхания в рев­матологической практике / Г.В. Дзяк // Укр. пуль­монол. журнал. – 2000. – №1. – С. 5–11.
  2. Карасьова О.В. Динаміка гострофазових по­казників у хворих на ідіопатичний легеневий фіброз протягом лікування / О. В. Карасьова, В. В. Родіонова, А. І. Шевцова // Тези наук. доп. наук.-практ. конф. «Актуальні питання внутрішньої медицини». – Дніпропетровськ, 2016. – С. 84-85.
  3. All cause Healthcare Costs and Mortality in Pa­tients with Systemic Sclerosis with Lung Involvement / A. Fischer, A. M. Kong, J. J.  Swigris [et al.] // J. Rheu­matol. – 2018. – N 2. – Р. 235-241.
  4. Antoniou K.M. Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension / K.M. Antoniou, G.A. Margaritopolous, N.S. Goh // Arthritis & Rheu­matol. – 2016. – N 4. – С. 1004-1012.
  5. Are physicians in primary health care able to recognize pulmonary fibrosis? [Електронний ресурс] / M. Purokivi, U. Hodgson, M. Myllärniemi [et al.] // Eur. Clin. Resp. J. – 2017. – Режим доступу до ресурсу:
  6. Fibrosis – a lethal component of systemic scle­ro­sis / Y. Y. Ho, D. Lagares, A. M. Tager, M. Kapoor // Na­ture Reviews Rheumatol. – 2014. – N 10. – Р. 390-402.
  7. Karas’ova O.V. The markers of inflammatory pro­cess activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis / O.V. Karas’ova, E.S. Khmel, E.N. Kovalenko, V.V. Rodionova // Eur. Resp. J. – 2012. – Vol. 40.
  8. King T.J. Idiopathic pulmonary fibrosis / T.J. King, A. Pardo, M. Selman // Lancet.- 2011.- N 378.- Р.1949-1961.
  9. Meyer K.C. Pulmоnary Fibrosis, Part I: Epi­de­miology, Pathogenesis, and Diagnosis / K.C. Meyer // Ex­pert Rev. Respiratory Medicine. – 2017. N 11. just-accepted.­NEJMoa1401739.
  10. Mora A. L. Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis / A.L. Mora, M. Bueno, M. Rojas // J. Clin. Investigation.- 2017. - N 2. - Р. 405-414.
  11. Richeldi L. Idiopathic pulmonary fibrosis / L. Ri­cheldi, H.R. Collard, M. G. Jones // Lancet. – 2017. – Vol. 389. – Р. 1941-1952.
  12. Suzuki A. The clinical impact of major comor­bi­dities on idiopathic pulmonary fibrosis / A. Suzuki, Y. Kon­doh // Respiratory Investigation. – 2017. – N 2. – Р. 94-103.
  13. The Four Corners Sign: A Specific Imaging Fea­ture in Differentiating Systemic Sclerosis-related Inter­sti­tial Lung Disease From Idiopathic Pulmonary Fibrosis [Електронний ресурс] / L. Walkoff, D.B. White, J.H. Chung [et al.] // J. Thoracic Imaging. – 2018. – Режим доступу до ресурсу: https://www.ncbi.­


This work is licensed under a Creative Commons Attribution 4.0 International License